Enrolling By Invitation
OBSERVATIONAL
NCT07018544
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study is conducted to investigate the safety and effectiveness of semaglutide in participants with obesity and overweight in routine clinical practice. Participants will get semaglutide as prescribed by a doctor. This study will last for about 4 years and participants will participate in the study for approximately 26 weeks.
Interventions
Name:
semaglutide
Type:
OTHER
Description:
Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Primary Outcomes
Measure:
Number (incidence) of AEs
TimeFrame:
From Visit 1 (baseline, 0 week) to Visit 4 (22 weeks < ~ ≤ 30 weeks)
Description:
Count of events
Trial Information
NCT ID
NCT07018544
Status
Enrolling By Invitation
Study Type
OBSERVATIONAL
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025